Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Authors: Maziarz RT; Center for Hematologic Malignancies, Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, OR., Waller EK; Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute of Emory University, Atlanta, GA., Jaeger U; Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria., Fleury I; Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada., McGuirk J; Department of Blood and Bone Marrow Transplant, The University of Kansas Cancer Center, Kansas City, KS., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B cell Malignancies, Oslo, Norway., Jaglowski S; The James Cancer Hospital and.; Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Schuster SJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Bishop MR; Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL., Westin JR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Mielke S; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet, Stockholm, Sweden.; Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden.; Center for Allogeneic Stem Cell Transplantation, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany., Teshima T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan., Bachanova V; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Foley SR; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada., Borchmann P; Department of Haematology and Oncology, University Hospital of Cologne, Cologne, Germany., Salles GA; Department of Hematology, Centre Hospitalier Lyon-Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France., Zhang J; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Tiwari R; Novartis Healthcare Pvt. Ltd, Hyderabad, India; and., Pacaud LB; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Ma Q; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Tam CS; Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia.
Source: Blood advances [Blood Adv] 2020 Feb 25; Vol. 4 (4), pp. 629-637.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2019001026